Logo image of RGNX

REGENXBIO INC (RGNX) Stock Price, Quote, News and Overview

NASDAQ:RGNX - Nasdaq - US75901B1070 - Common Stock - Currency: USD

10.4  +0.57 (+5.8%)

After market: 10.37 -0.03 (-0.29%)

RGNX Quote, Performance and Key Statistics

REGENXBIO INC

NASDAQ:RGNX (5/2/2025, 8:21:16 PM)

After market: 10.37 -0.03 (-0.29%)

10.4

+0.57 (+5.8%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High17.35
52 Week Low5.04
Market Cap521.25M
Shares50.12M
Float46.30M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-12 2025-05-12/amc
IPO09-17 2015-09-17


RGNX short term performance overview.The bars show the price performance of RGNX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

RGNX long term performance overview.The bars show the price performance of RGNX in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of RGNX is 10.4 USD. In the past month the price increased by 55.92%. In the past year, price decreased by -38.21%.

REGENXBIO INC / RGNX Daily stock chart

RGNX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.57B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.30B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About RGNX

Company Profile

RGNX logo image REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 353 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The firm is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Company Info

REGENXBIO INC

9804 Medical Center Drive

Rockville MARYLAND 20850 US

CEO: Kenneth T. Mills

Employees: 353

RGNX Company Website

RGNX Investor Relations

Phone: 12405528181

REGENXBIO INC / RGNX FAQ

What is the stock price of REGENXBIO INC today?

The current stock price of RGNX is 10.4 USD. The price increased by 5.8% in the last trading session.


What is the ticker symbol for REGENXBIO INC stock?

The exchange symbol of REGENXBIO INC is RGNX and it is listed on the Nasdaq exchange.


On which exchange is RGNX stock listed?

RGNX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for REGENXBIO INC stock?

18 analysts have analysed RGNX and the average price target is 33.58 USD. This implies a price increase of 222.84% is expected in the next year compared to the current price of 10.4. Check the REGENXBIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is REGENXBIO INC worth?

REGENXBIO INC (RGNX) has a market capitalization of 521.25M USD. This makes RGNX a Small Cap stock.


How many employees does REGENXBIO INC have?

REGENXBIO INC (RGNX) currently has 353 employees.


Is REGENXBIO INC (RGNX) expected to grow?

The Revenue of REGENXBIO INC (RGNX) is expected to grow by 246.79% in the next year. Check the estimates tab for more information on the RGNX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy REGENXBIO INC (RGNX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does REGENXBIO INC (RGNX) stock pay dividends?

RGNX does not pay a dividend.


When does REGENXBIO INC (RGNX) report earnings?

REGENXBIO INC (RGNX) will report earnings on 2025-05-12, after the market close.


What is the Price/Earnings (PE) ratio of REGENXBIO INC (RGNX)?

REGENXBIO INC (RGNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.56).


What is the Short Interest ratio of REGENXBIO INC (RGNX) stock?

The outstanding short interest for REGENXBIO INC (RGNX) is 11.34% of its float. Check the ownership tab for more information on the RGNX short interest.


RGNX Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to RGNX. When comparing the yearly performance of all stocks, RGNX turns out to be only a medium performer in the overall market: it outperformed 40.38% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

RGNX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to RGNX. RGNX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RGNX Financial Highlights

Over the last trailing twelve months RGNX reported a non-GAAP Earnings per Share(EPS) of -4.56. The EPS increased by 24.38% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -48.74%
ROE -87.46%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%29.37%
Sales Q2Q%-4.5%
EPS 1Y (TTM)24.38%
Revenue 1Y (TTM)-7.63%

RGNX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to RGNX. The Buy consensus is the average rating of analysts ratings from 18 analysts.

For the next year, analysts expect an EPS growth of 89.11% and a revenue growth 246.79% for RGNX


Ownership
Inst Owners89.3%
Ins Owners7.33%
Short Float %11.34%
Short Ratio5.25
Analysts
Analysts84.44
Price Target33.58 (222.88%)
EPS Next Y89.11%
Revenue Next Year246.79%